Clinical efficacy and safety of afatinib in the treatment of non-small-cell lung cancer in Chinese patients.

Release time:2023-02-13

Impact Factor:4.345

DOI number:10.2147/OTT.S136579

Affiliation of Author(s):Xiangya Hospital, Central South University

Teaching and Research Group:Department of Clinical Pharmacology

Journal:OncoTargets and therapy

Place of Publication:New Zealand

Key Words:afatinib, NSCLC, Chinese patients, drug resistance, side effect, companion diagnosis

Abstract:Compared with various malignant tumors, lung cancer has high incidence and the highest mortality worldwide. Non-small-cell lung cancer (NSCLC), the most common kind of lung cancer, is still a great threat to the world, including China. Surgery, platinum-based chemotherapy, and radiotherapy are still the primary treatments for NSCLC patients in the clinic, whereas immunotherapy and targeted therapy are gradually playing more important roles. A next-generation tyrosine kinase inhibitor (TKI), afatinib, was developed as a targeted reagent for epidermal growth factor receptor (EGFR). This targeted drug was effective in a series of trials. The US Food and Drug Administration then approved afatinib as a new first-line treatment for EGFR L858R and exon 19 deletion mutant patients in 2013. This review focused on current clinical studies of afatinib. Although this TKI was not widely available in China until recently, we aim to provide a reference for its future use in China.

Co-author:Jia-Jia Cui, Ao-Xiang Guo

First Author:Lei-Yun Wang

Indexed by:Journal paper

Correspondence Author:Ji-Ye Yin

Discipline:Medicine

First-Level Discipline:Pharmaceutical Science

Document Type:J

Volume:11

Issue:1

Page Number:529-538

ISSN No.:1178-6930

Translation or Not:no

Date of Publication:2018-01-24

Included Journals:SCI

Links to published journals:https://www.dovepress.com/clinical-efficacy-and-safety-of-afatinib-in-the-treatment-of-non-small-peer-reviewed-fulltext-article-OTT